news

  • 4 November 2019
    X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Derek Meisner, J.D., as General Counsel. Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance.

    “As a strategic and solution-oriented executive, Derek brings his broad legal and business experience to support X4’s high growth trajectory and is an important and welcome addition to our team,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “We look forward to Derek’s leadership as we continue to grow as a public company and work to develop and commercialize innovative therapies for the treatment of rare diseases.”

    “I am thrilled at the opportunity to work alongside this talented and dedicated team at X4 and am eager to contribute my background and expertise toward the company’s continued growth and success as we advance novel therapies for rare disease patients with limited treatment options,” commented Mr. Meisner.

    Most recently, Mr. Meisner held the role of General Counsel at Genocea Biosciences, a Cambridge-based, publicly traded, clinical-stage biopharmaceutical company. Prior to Genocea, he served as General Counsel of multiple Boston-based financial services firms, including prominent life science investor RA Capital Management, and he was previously a partner at the international law firm K&L Gates and Branch Chief in the Division of Enforcement of the U.S. Securities and Exchange Commission. Mr. Meisner holds a B.A. from the University of Michigan and a J.D. from the Washington College of Law at American University.